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Introduction. Domestic transmission now appears to be the principal route of Leishmania
panamensis infection in deforested regions characterized by the replacement of primary forest
by permanent plantations, i,e coffee or cacao crops. This paper presents the results of the
disease patterns in a representative population of the Opón focus, in Santander, Colombia.
Objective. The principal aims were: 1) to measure the incidence rate in a representative
population of the Opón focus; 2) to identify demographic risk factors for infection; 3) to estimate
the proportion of infections which cause disease; 4) to estimate the protection against disease
from acquired immunity; 5) to estimate the frequency of reactivations, and 6) to estimate the risk
of mucosal leishmaniasis.
Material and methods. A 19 month prospective survey of leishmaniasis caused by Leishmania
panamensis was carried out amongst 1380 people in a cacao growing region of Santander
Department, Colombia. The population was diagnosed clinically and by the Montenegro skin
test (at two time points).
Results: The incidence rate was 0.19 infections/person-year, with 31% of infections apparently
subclinical. The risk of acquiring cutaneous leishmaniasis decreased with age even in the
absence of apparent previous infections. Protective immunity followed both clinical and
subclinical infections, persisting for at least 10 years after a primary lesion. Mucocutaneous
leishmaniasis was detected in 12% of the population with cutaneous lesions, of which 77% had
mild symptoms, and 23% perforated nasal septa. The risk of mucosal leishmaniasis was greatest
for males, and for people whose primary cutaneous lesion was on the head.
Conclusion. The average age of infection in Opón, 7.7 years (1/λ), and the absence of gender
as a risk factor is highly indicative of intradomiciliary or peridomiciliary transmission.
Key words: Leishmania, epidemiology, cutaneous leishmaniasis, mucocutaneous
leishmaniasis.
Transmisión de Leishmania panamensis en ambientes domésticos: resultados de un
estudio epidemiológico prospectivo en Santander, Colombia
Introducción. La transmisión doméstica de Leishmania panamensis parece ser la fuente de
infección mas frecuente en regiones deforestadas, caracterizadas por el reemplazo del bosque
primario por plantaciones permanentes como cacao y café.  Este papel presenta los resultados
de los patrones de enfermedad en una población representativa del foco del Opón, en
Santander, Colombia.
Objetivo. Los objetivos principales fueron: 1) cuantificar la tasa de incidencia en una población
representativa de la población del foco del Opón; 2) identificar los factores de riesgo
demográficos para la infección; 3) estimar la proporción de infecciones que causan enfermedad;
4) estimar la protección contra la enfermedad según la inmunidad adquirida; 5) estimar la
frecuencia de reactivaciones, y 6) estimar el riesgo de leishmaniasis mucosa.
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Materiales y métodos: Se llevó a cabo un estudio prospectivo de leishmaniasis causada por
Leishmania panamensis durante 19 meses, entre 1.380 personas habitantes de una región
cacaotera del departamento de Santander, Colombia.  La población fue diagnosticada por
clínica y por la prueba de Montenegro (en dos tiempos).
Resultados: La tasa de incidencia fue de 0,19 infecciones/persona-año, 31% de los cuales
tuvieron una infección aparentemente subclínica. El riesgo de adquirir leishmaniasis cutánea
decrece con la edad aún en ausencia de infecciones previas aparentes. Una inmunidad
protectiva subsiguió a las infecciones clínicas y subclínicas, persistiendo por lo menos durante
10 años posterior a una infección primaria. La leishmaniasis mucocutánea se detectó en 12%
de la población con lesiones cutáneas, de las cuales 77% tuvieron síntomas no severos, y
23% perforación del tabique nasal. El riesgo de leishmaniasis mucosa fue más grande para
hombres y para personas cuyas lesiones primarias se localizaron en la cabeza.
Conclusión. El promedio de edad de infección en el Opón, 7,7 años (1/λ), y la ausencia de
factores de riesgo relacionados con el género indican que la transmisión es intra o peri
domiciliaria.
Palabras clave: Leishmania, epidemiología, leishmaniasis cutánea, leishmaniasis
mucocutánea.
Leishmania (Viannia) panamensis is responsible
for zoonotic cutaneous leishmaniasis and occa-
sionally mucocutaneous leishmaniasis  in eight
countries in Central and South America (1,2). The
total number of human cases caused by L.
panamensis annually is unknown, as i) most cu-
taneous leishmaniasis cases are not reported (3),
ii) L. panamensis is often sympatric with other
Leishmania species responsible for cutaneous
leishmaniasis (e.g. Leishmania braziliensis), and
iii) the Leishmania species responsible for the re-
ported cases are rarely identified.
However, on the basis of those few human isolates
which have been characterized, it appears that
about half of all cutaneous leishmaniasis cases
reported each year within the eight endemic
countries are due to L. panamensis (2). This
percentage varies from less than 1% in Guatemala
to over 90% in Panama and Costa Rica. In
Colombia, about 50% of all cutaneous
leishmaniasis cases reported are due to L.
panamensis; but this represents the greatest
number of reported cases caused by L.
panamensis in any country (an estimated 3,000/
year) (2).
The geographic distribution of L. panamensis co-
incides with the overlapping distribution of the two-
toed sloth Choloepus hoffmanni thought to be the
principal reservoir host, and the sandfly species
Lutzomyia trapidoi and Lutzomyia ylephiletor,
thought to be the principal vectors (4). Hence, the
classical risk factors for human infection, as de-
scribed in Panama (5) and on the Pacific coast of
Colombia (6) involve occupational exposure to in-
fectious sandfly bites when adult male humans
enter the forest.
Indeed, the requirement of forest habitat for the
survival of sloth populations led Herrer and
Christensen to write optimistically in 1976 that the
“increased deforestation activities by new immi-
grants to provide more farm land may soon dis-
rupt the transmission cycle of Leishmania which
will lead to the disappearance of the disease.” In
fact, the history of the last 25 years is that while
the deforestation of endemic areas has continued
unabated, the incidence rate of L. panamensis has
increased steadily. How has this been possible?
Part of the answer lies in the changing patterns of
L. panamensis transmission. Persistently endemic
communities, characterised by a high prevalence
of active lesions in children and apparent domestic
transmission, were occasionally detected in
Panama in the 1970s, e.g. in El Aguacate (7).
However, this epidemiological pattern has only
recently become widespread, with all household
members now apparently at risk of infection in
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many endemic zones of L. panamensis. For ex-
ample, domestic transmission now appears to be
the principal route of L. panamensis infection in
the provinces of Esmeraldas and Pichincha on
the Pacific coast of Ecuador (8), a deforested
region characterized by the replacement of pri-
mary forest by coffee plantations, and by relatively
high densities of Lutzomyia trapidoi and Lutzomyia
gomezi in and around houses. Domestic trans-
mission of L. panamensis is also suspected in
Acosta, Costa Rica, where the presumed sandfly
vectors, L. ylephiletor and L. gomezi, are abun-
dant in the coffee plantations that have replaced
the primary forest (9,10).
Because the course of  cutaneous leishmaniasis
infection depends on both the age and immune
status of patients (11,12) the change in L.
panamensis transmission from sylvatic to domes-
tic could also affect the characteristic clinical
symptoms of an exposed population.
This paper describes the results of the first pro-
spective survey to investigate the course of in-
fection in a population apparently exposed to L.
panamensis in the domestic environment (Angulo
and others, unpublished data): the inhabitants of
the Opón focus in Colombia. The principal aims
were (1) to measure the incidence rate in a repre-
sentative population of the Opón focus, (2) to iden-
tify demographic risk factors for infection, (3) to
estimate the proportion of infections which cause
disease, (4) to estimate the protection against dis-
ease from acquired immunity, (5) to estimate the
frequency of reactivations, and (6) to estimate the
risk of mucosal leishmaniasis.
Materials and methods
Study site
The study was carried out in 12 villages in the
Opón area, Landázuri municipality (6° 20' N; 73°,
43' W), Santander Department at altitudes ranging
from 400 to 1,200 m above sea level. It is a
mountainous region where the principal economic
activities are silviculture of tropical hard woods
(in the rain forest), cattle ranching, and the cacao
crops. The relative abundance (in percentage) of
the vegetation around houses was estimated by
eye within concentric circles with radiuses from
the house of 50 m, 100 m, 200 m, 300 m, and 800
m, respectively. Most houses adjoin pasture land
(ca. 80%) and/or cacao plantations (ca. 40%), and
are some distance away from the surviving
patches of primary or secondary forest. About 35%
and 85% of houses are within 800m from primary
and secondary forest, respectively.
Study design and population
During the first visit in January, 1995, a scaled
map for each village was completed and all 527
occupied houses recorded. A unique identification
number was allocated to each person in every
household and the Colombian national identity card
was requested in order to verify the date of birth.
If possible, the whole family attended the
interviews in order to minimise recall bias.
Demographic data (age, sex, and date of
immigration, when appropriate) and clinical status
(including age when infected) were recorded, and
a proportion of the population (those giving
consent) were given a Montenegro skin test (April-
June, 1995).
All households were visited five times at about
three month intervals following the initial cross-
sectional survey, checking for changes in the
study population (due to immigration, emigration,
birth or death) and looking for new cutaneous or
mucocutaneous leishmaniasis cases.
During the final visit (February-March, 1997) the
study population was given a second Montenegro
skin test an average of 19 months after the first
one using the same batch of antigen as before. In
1995 the Montenegro skin test  was applied to
51% of the Opón population (1,380/2,704), of which
55.5% (766) received a second one.
There were no differences by gender between the
group remaining in the project and the emigrants/
refusal group; nevertheless, the former were
slightly older (mean=20.8 years old) than the latter
(mean=18.2 years old) (Kruskal-Wallis H: 7.303,
P=0.006).
The great majority of refusals were adults with a
positive result in the first Montehnegro skin test.
Thus, the main possibility of bias due to the re-
fusal would apply to the measurement of recov-
ery rate (r) rather than the measurement of trans-
mission rate. During the prospective study, 163
134
Biomédica 2006;26(Supl.1):131-44MUÑOZ G., DAVIES C.R.
emigrants, 10 deaths, 126 immigrants and 37 births
were recorded in the study population. Analysis
incorporating age were carried out on a reduced
data set of 1,333 persons, because of missing
data from 47 people.
Clinical diagnosis
Past cases of cutaneous leishmaniasis were iden-
tified by characteristic scars, which were detected
using the following criteria: no history of trauma,
duration for more than 2 weeks, central depressed
surface and contours with no sharp angles. Sus-
pected leishmaniasis lesions were defined by the
absence of prior history of trauma and more than
two weeks of evolution. Confirmation of the aeti-
ology of suspected lesions was made by a positive
result from one or more diagnostic tests (13), with
the informed written consent of the patients. These
included: 1) microscopic examination of Giemsa-
stained slides made from dermal scrapings; 2)
PCR using the B1 and B2 primers as described
by de Bruijn (1992) (14), and 3) the in vitro culture
of parasites from aspirates or biopsies in NNN
biphasic medium. The sensitivity of  microscopy
diagnosis was 40% for  all suspected patients and
60% for the 55 patients with a positive culture,
while the equivalent values for PCR were 43%
and 87%.
All confirmed patients were provided with free treat-
ment (Glucantime®) and followed-up on a monthly
basis. Characterisation of Leishmania isolates was
carried out by IEA in thin-layer starch-gel electro-
phoresis, using 8 isoenzymes  (PEPD, NH, MPI,
ME, GPI, PGM, 6PGD, and ES) as described by
Godfrey and Kilgour (1976) (15). All 25 parasites
isolated during the survey were characterised as
L. panamensis; 23 were indistinguishable from the
reference strain MHOM/PA/71/LS94, and two
isolates demonstrated  the same variant of PEPD.
After clinical inspection and following the results
of the diagnostic tests, the study population was
classified into two groups: people with scar or
lesions (L+) and people with no history of
leishmaniasis (L-). The upper respiratory tract was
visualised with the help of a nasal speculum,
lantern and a tongue depressor by a trained clini-
cian (16) on the L+ population. Lesions compat-
ible with mucosal leishmaniasis were defined as
septal erosion or perforation; erythema or ulcers
in the septum, turbinate, oral or nasal mucosa. In
order to exclude acute lesions the clinician visited
the same population three times in three consecu-
tive months. Persistent lesions were included as
suspected a mucocutaneous leishmaniasis patient
but biopsy was not taken because there was not
hospital aid in such remote areas.
Montenegro skin tests
The Montenegro skin test was applied (with their
informed written consent) to some or all of the
residents of 331 households following the
technique recommended by the World Health
Organization (17), i.e. using a mixture of L.
panamensis and L. braziliensis at a concentration
of 5x106 ml-1 heat-killed promastigotes for each
species. A pressurised intradermal injector
(Dermo-jet model G, Robbins Instruments, USA)
was used to inject 0.1 ml of leishmanin
intradermally on the external surface of one arm,
and the diameter of induration was measured 48
hours later. The choice of cut-off point, 3 mm,
was made empirically, and the study population
with a Montenegro skin test  was classified into
two groups according to their skin test response:
Montenegro negative (M-) and Montenegro posi-
tive (M+).
Ethical aspects
Written informed consent was obtained from every
person or family included in the present study,
following the indications of the Ministerio de Salud
de Colombia (Resolution 008430, 1993). In
addition, approval was requested and obtained
from the ethical committee of the Industrial
University of Santander
Analysis
The transmission rate was measured using the
results of both the cross-sectional and prospective
studies. The analysis of the cross-sectional data
focused on the comparison of prevalence rates
(active or cumulative; Montenegro skin test re-
sponsiveness or clinical) according to sex and
age. In addition, a simple infection-recovery model
(11) was fitted to the age prevalence curves (i.e.
the proportion that were infected at age “a”) by
maximum likelihood (18). The model assumes that
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susceptibles became infected at a constant rate
“l“ (the force of infection), and infected recovered
and returned to the susceptible class at a con-
stant rate “r“ (the recovery rate).  It follows that
the proportion infected at age “a” can be predicted
from the equation:
The assumptions of these models were then tested
by analysing the results of the prospective survey,
which permitted direct estimates of incidence (in
relation to age or gender) and recovery rate during
the 19 month follow-up period.
Explanatory variables for variation in infection rate
or in the clinical consequences of infection were
mostly sought using general linearised models in
GLIM (v. 4.07) (19). When the outcome data were
counts (e.g. the number of scars), Poisson errors
were specified; and when the outcome data were
proportions (e.g. prevalence) or binary (e.g. healthy
versus with disease) these were treated as
binomial variables in logistic regression. When no
suitable error structure could be identified, a non-
parametric method was adopted.
For multivariate analyses model simplification to
the minimal adequate model was achieved by
backward stepwise elimination. The absolute or
relative change in residual deviance caused by
the removal of each explanatory term was
examined for significance (P<0.05). Interaction
terms were assessed and removed in order of
diminishing complexity, i.e. before the main effect
terms. This procedure was repeated until the minimal
adequate model retained only significant explana-
tory variables. For minimal adequate models with
binomial or Poisson error structures, changes in
residual deviance were compared to χ2 distribu-
tion. The F-ratio statistic was employed to test
models with a normal error distribution. Finally,
the fit of each model was checked by inspecting
a plot of the residuals against the fitted values.
Results
Population infection rate
The distribution of induration sizes suggest a bi-
modal-like shape (figure 1,2) indicating a differen-
tial response between uninfected and infected
people. In order to define a cut-off point for M+,
the distribution of Montenegro skin test induration
sizes was compared between L+ and L- people. It
is clear from these data that there is no empirical
reason for choosing the textbook cut-off point of
5 mm, as the majority of the 10 people with indu-
ration sizes between 1-4 mm also had scars. In
contrast, clinical cases were a small minority
Figure 1. Frequency distribution of Montenegro skin test
(MST) induration sizes amongst healthy population.
Figure 2. Frequency distribution of Montenegro skin test
(MST) induration sizes amongst patients with cutaneous
lesions (black bars) and scarred population (white bars).
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amongst those with a zero skin test response.
Given the few data, the choice of cut-off point
between 1-4 mm must be somewhat arbitrary. In
the analysis described here, we used a relatively
conservative cut-off point of 3 mm, i.e., induration
sizes of 3 mm or greater are treated as a positive
skin test response or “M+”.
The cumulative Montenegro skin test prevalence
of infection amongst the whole study population
in 1995 was 0.75 (1,044/1,380) (table 1). The in-
duration sizes of the skin test response accord-
ing to clinical status was as follows: 1) people
with active cutaneous lesions (no mucosal), n=80;
geometric mean (gm)=8.0 mm (95% Confidence
Intervals [CI] 7.8-8.2 mm); 2) cutaneous scarred
population (no mucosal), n=782; gm=12.2 mm
(95%CI 12.1-12.2 mm); 3) people with mucocuta-
neous lesions, n=108 (concurrent active cutane-
ous lesions, 8; concurrent cutaneous scars, 100);
gm=15.6 mm (95%CI 14.2-17 mm), and 4)
“healthy” people, n=410; gm=1.0 mm (95%CI 0.9-
1.1 mm).
In order to determine the average incidence rate
in recent years, the force of infection (λ) was cal-
culated by fitting a simple infection-recovery model
to the cross-sectional age prevalence data for M+
(18), making the assumption of constant trans-
mission and recovery rate with time and age. The
model estimates a mean recovery rate of 0.01/
year, and l to be 0.14 (95%CI 0.12-0.15) cases/
person-years (figure 3), which is significantly
Figure 3. Montenegro skin test (MST) prevalence by age
for (a) females and (b) males. Age prevalence curves for
the population with MST positive response (M+) detected
during the cross-sectional study (1995). Each point repre-
sents the proportion M+ within a particular age group. Lines
were fitted by maximum likelihood to the infection-recovery
model (see text for details).
Table 1. Distribution of the study population by clinical and Montenegro skin test (MST) status in the 1995 and 1997 cross-
sectional surveys.
Status 1995  Status 1997
Clinical MST 2nd New lesions No new lesions
status status n MST M+ M- NT* M+ M- NT
Cutaneous lesions
M+ 75 50 1 0 2 49 0 23
M- 13 6 0 0 0 4 2 7
Scarred population
M+ 852 439 16 0 4 414 9 409
M- 30 15 1 1 0 5 8 15
Healthy population
M+ 117 51 5 0 3 39 7 63
M- 293 205 36 8 5 16 145 83
Total 1380  766  59 9 14 527 171 600
*M+: positive MST response; M-: negative MST response; NT: not tested
137
Biomédica 2006;26(Supl.1):131-44 LEISHMANIA PANAMENSIS EPIDEMIOLOGY
smaller than the Montenegro skin test conversion
rate detected during the prospective survey. The
mean number of person-months at risk between
the first and second skin test date was 19 months.
Amongst the 226 M- people who were re-tested,
62 converted to M+, resulting in an incidence of
0.21 (95%CI 0.17-0.24) conversions/person-year
(Only 5 people in the second skin test presented
size of 3 or 4mm). Evidence of past infections
were detected in 10 people (6 scars, 4 lesions)
who converted from M-1995 to M+1997 (table 1), sug-
gesting that these conversions reflect infections
already prevalent in 1995 but with an extended
incubation period prior to skin test conversion,
rather than incident infections during the prospec-
tive study. Thus, our most reliable assessment
of incidence rate is 0.19 (95%CI 0.15-0.23) con-
versions/person-year which is calculated from the
52/205 M-L-1995 who converted during the 19 month
prospective study.
During the prospective survey, loss of positive
skin test responsiveness was detected in 16
people at a rate, r, of 0.02 (95%CI 0.01-0.03)/
person-year. Recovery rate was significantly
greater in people without clinical symptoms, 0.13
(7/51), than amongst L+ people, 0.02 (9/439)
(χ2=16.2, degrees of freedom [df]=1, P<0.0001).
The assumption of constant transmission rate with
time was validated by a cross-sectional survey
carried out on the same population in 2004
(n=1,127) , i.e. seven years after the first survey
(1997). The force of infection (λ) calculated by
fitting a simple infection-recovery model to the
cross-sectional age prevalence data in 2004 was
0.12 (95%CI 0.11-0.14), i.e. remarkably close to
the previous estimate.
Risk factors for infection
The cumulative prevalence of infection for males,
0.77 (535/692)/person was not significantly greater
than that for females, 0.73 (509/688)/person:
χ2=2.08, df=1, P=0.15. In the follow-up study, in-
cidence of infection in males, 0.24 (26/109 M-1995
re-tested)/person-year, was also not significantly
different from the incidence of infection in females,
0.30 (36/117)/person-year (χ2=1.35, df=1, P=0.24).
Similarly, l estimated from the age MST preva-
lence curves for males, 0.14 (95%CI 0.11-0.16)/
person-year was not significantly different from l
calculated for females, 0.12 (95%CI 0.10-0.13)/
person-year (figure 3). Thus, there is no evidence
of any difference in the risk of infection between
males and females.
Because of the relatively high transmission rate
in the Opón focus, the majority of  M-1995 (224/
336) are concentrated amongst children less than
10 years old. This explains the relatively low mean
age of 8.6 (95%CI 6.7-10.5) years amongst the
62 people who converted during the study. How-
ever, there was no significant difference between
the mean age of the people who remained M- in
1997, 10.2 (95%CI 8.4-11.9) years, compared to
the mean age of “converters” (t test on log trans-
formed data t=1.55, df=1, P>0.05). The absence
of any relationship between age and risk of
infection is illustrated in figure 4, which demon-
strates that there is no trend between the inci-
dence rates calculated for eight age groups (with
equal denominators) (F=0.05, df=1, P>0.05). Thus,
new infections occurred irrespective of age,
validating the key assumption made in the infec-
tion-recovery model to calculate l from age preva-
lence data.
Risk factors for clinical symptoms with
infection
The most reliable estimate of the proportion of
infections leading to clinical disease comes from
the prospective data. The proportion of skin test
conversions which lead to disease (a) was 0.69
Figure 4. Montenegro skin test conversion rate by age.
Squares are the proportions converting in each age class
over the 19 month period, and lines are the standard errors.
The horizontal line is the average conversion rate.
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(95%CI 0.56-0.82) [36/52]. The possibility that
some of the “subclinical” skin test conversions
were cross-reactions cannot be discounted. How-
ever, no significant difference was detected in the
induration sizes of the skin test response follow-
ing “subclinical” infections (6.7 mm; 95%CI 5.3-
8.6 mm) compared to the response following clini-
cal incident infections (6.5 mm; 95%CI 5.8-7.2
mm) (t-test on log transformed data: t=0.29; df=51;
P=0.76).
The significance of age and gender was tested by
comparing the two subpopulations of people with
incident subclinical (SC) or clinical (C) infections.
The geometric mean age for C, 3.8 years (95%CI
2.8-5.1 years), was significantly smaller than for
SC 8.7 years (95%CI 6.6-11.3 years) (t-test on
log transformed data: t=3.3; df=51; p=0.0021).  The
sex ratio amongst SC cases, 43.7% male (7/16),
was not significantly different from that amongst
C cases, 47.2% male (17/36) (χ2=0.05, df=1,
P>0.05).
Acquired immunity against disease
During the follow up, 82 cutaneous leishmaniasis
patients were clinically and laboratory diagnosed
(table 1). In order to determine the role of acquired
immunity for protecting against new episodes of
clinical leishmaniasis, risk factors for cutaneous
leishmaniasis were sought by testing for signifi-
cant associations with the presence of cutaneous
leishmaniasis (as a binary response) amongst the
population of 1,333. The explanatory variables
tested in the multivariate model were village, age,
gender, Montenegro skin test induration size, and
previous lesion (intercept estimate -1.439). Sig-
nificant risk factors were age (χ2=14.5, P<0.001;
estimate -0.05635), skin test size (χ2=4.2, P<0.05;
estimate -0.246), and previous lesions (χ2=10.7,
P<0.01; estimate -2.019), and there was a signifi-
cant interaction effect between MST size and clini-
cal status (χ2=4.2, P<0.05).
The main conclusions are as follows: 1) irrespec-
tive of Montenegro skin test and clinical status,
the odds of a new lesion decreased significantly
with age by 5.4% per year; 2) amongst both the
healthy and scarred population, the odds of a new
lesion decreased with skin test size; this effect
was significantly greater amongst the healthy
population, for which the odds of a new lesion de-
creased by 22% per 1 mm increase in skin test
size; this compares to an equivalent reduction of
9% for the scarred population; 3) irrespective of
age and Montenegro skin test status, the odds of
a new lesion was significantly less for the scarred
than for the healthy population; but this effect was
less marked for people with a greater skin test
size. For example, for a person with no skin test
response (0 mm), the odds of a new lesion de-
creased by 88%, whereas for people with skin test
responses of 10 mm the odds decreased by only
43% .
Recurrent leishmaniasis
Full clinical histories were recorded for 125 of the
170 cutaneous leishmaniasis patients in the study
(i.e. the 88 patients detected in the first cross-
sectional survey, plus the 82 new cases detected
during the prospective survey) . Previous leish-
maniasis scars were detected in 80 (64%) of these
patients. Incidence decreased from 0.12 to 0.016
cases/person-years in the first 10 years after the
primary lesion (figure 5), indicating that these early
secondary infections were relapses rather than re-
infections. However, 15 years after the primary
infection, incidence rates increase to a peak of
0.091 cases/person-years, which is not signifi-
cantly different from the incidence in L-1995 (0.1
cases/person-years) (figure 5). The precise
localisation of lesions and the time since primary
lesions occurred were recorded on the clinical his-
tory forms. For 36% (29/80) of the patients, the
secondary lesions appeared in the same site in
Figure 5. The incidence rate of secondary lesions (+
standard errors) in relation to time since the primary lesion.
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the body as the previous scars. For this popula-
tion, the geometric mean time between the pri-
mary and secondary lesions was 2.2 years (95%CI
0.71-3.74 years). In contrast, the mean time
between episodes when secondary lesions were
on a distant site was 9.3 years (median 3 years)
which was significantly higher than for the former:
H (Kruskal-Wallis)=4.83, df=1, P=0.027.
Mucocutaneous leishmaniasis
Clinical inspections for mucocutaneous leishma-
niasis were carried out on 881 persons with cur-
rent or past cutaneous leishmaniasis symptoms,
of which 12% (108) presented lesions clinically
compatible with mucocutaneous leishmaniasis.
The majority (77%) of the mucocutaneous leish-
maniasis symptoms were mild, i.e. with erythema,
ulcers or erosion detected on single mucosa, usu-
ally the nasal septum but, also, the nasal mu-
cosa (n=18), oral mucosa (n=2) and turbinate
(n=2). The remaining 23% (n=25) had moderate
symptoms (perforated nasal septa) (table 2).
There was some evidence that severity increased
with time since cutaneous leishmaniasis episode,
as the geometric mean time for mild mucocuta-
neous leishmaniasis was 7.5 years (95%CI: 5.3-
9.8 years) compared to 21.4 years (95%CI: 19-
23.7 years) for moderate cases (t=4.11, df=1,
P<0.001). Risk factors for mucocutaneous
leishmaniasis were sought by testing for significant
associations with the presence of mucocutaneous
leishmaniasis (as a binary response) amongst the
881 cutaneous leishmaniasiscases observed.
The explanatory variables tested in the multivari-
ate model were: 1) whether the cutaneous leish-
maniasis lesions were active or healed, and the
time since the cutaneous leishmaniasis episode;
2) the area, number and localisation of the cuta-
neous leishmaniasis lesions; 3) the Montenegro
skin test induration size; 4) whether the cutane-
ous leishmaniasis lesion was treated with anti-
monials; and 5) age and gender. The  significant
risk factors for mucocutaneous leishmaniasis were
gender (P<0.0001; odds ratio [OR] for males=2.2
[95%CI 1.4-3.4]), location of cutaneous leishma-
niasis lesion on the head (P=0.002; OR=2.0
[95%CI 1.3-3.0]), Montenegro skin test size
(P=0.001; OR for unit increase in log transformed
Montenegro skin test induration in mm=2.4 [95%CI
1.4-3.9]) and previous treatment (P<0.001;
OR=2.3 [95%CI 1.5-3.7]).
Discussion
Personal risk factors for infection are most
accurately estimated from prospective studies
with two assessments of Montenegro skin test
status in the population. Correlates with infection
rate can then be identified either by cohort studies
(as in this study) or by nested case-control studies
(Llanos-Cuentas, unpublished data). In contrast,
retrospective studies of infection, whether by case-
control studies (20) or cohort studies, are plagued
Table 2.  Relationship between mucocutaneous (MCL) clinical features and time since cutaneous (CL) lesions.
Number of MCL patients by type of lesions
Time since CL* erythema Nasal lesions erosion Septum
ulcers  perforation
0-3 15 3 1 1
4-6 13 1 1
7-9 8 3 1 1
10-12 6 1 2
13-17 4 3
18-20 3
 more than 23  6 3 9
total patients  55 9 4 17
Geometric mean† 7,1 8,7 10 21,4
*: time since cutaneous lesions by groups (in years)
†: geometric mean time since cutaneous lesions (in years)
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by potential bias and other inaccuracies
associated with faulty recall or changes in
circumstance. Thus, here we focus on the
comparison of our results with those from the only
two previously published large scale prospective
Montenegro skin test  surveys of New World
cutaneous leishmaniasis: in Tumaco, Colombia
(6) and in the Peruvian Andes (11).
New infections occurred irrespective of age and
gender in Opón and in Perú, whereas in Tumaco
incidence of infection increased with age, and in-
fection was three times greater in males than in
females. These differences are presumably the
result of differences in exposure rather than dif-
ferences in susceptibility. The average age of in-
fection in Opón, 7.7 years (1/λ), and the absence
of gender as a risk factor is highly indicative of
intradomiciliary or peridomiciliary transmission, as
in the Peruvian Andes. In Tumaco, infection mainly
occurs during farming activity, an occupation in
Colombia carried out principally by males. The
epidemiological contrast with Tumaco is striking,
given the similarities between Opón and Tumaco
both in the agent of disease (L. panamensis) and
in the presumed principal vectors (Lu. trapidoi, and
Lu. gomezi).
Clinical infection is determined by the host-para-
site interaction which includes host genetic fac-
tors, acquired resistance to infections, and para-
site pathogenicity. Our estimates of pathogenic-
ity from the cross-sectional and prospective sur-
veys are surprisingly different. The explanation
appears to lie in the significant difference between
the recovery rate of Montenegro skin test respon-
siveness following subclinical or clinical infections.
Subclinically infected people apparently revert to
M- relatively quickly, so that despite a relatively
high transmission rate, only a small proportion of
people sampled in the cross-sectional survey re-
tain their M+L- status. Hence, our best estimate
for the proportion of subclinical infections in the
Opon focus was 31%. This is higher than the rate
reported for L. peruviana in Peru (17%) but lower
than that reported in Tumaco (88%) (6,11).
This result is consistent with the hypothesis that
L. panamensis in Opón is more pathogenic than
in Tumaco, and that L. peruviana is more patho-
genic than both L. panamensis populations stud-
ied in Colombia. Alternatively, the differences may
represent methodological inconsistencies between
the three research groups, i.e. different sensitivi-
ties of the clinical or Montenegro skin test diag-
nosis (due to different field workers or different
leishmanin batches), including the hypothetical
possibility of a booster effect from serial skin test-
ing. In addition, geographical differences could be
explained by different levels of cross-reacting
parasitic infections in the three regions such as
lizard Leishmania (21).
The proportion of subclinical infections may also
be influenced by factors related to human sus-
ceptibility. In Tumaco the majority of the commu-
nity are negros who are infected when adults,
whilst in Opón the people are whites and “mulatos”
(i.e. a mixture of indigenous, Spaniards and
negros) infected in childhood. Evidence that
people who developed chronic disease in Tumaco
were innately more susceptible than those who
were subclinically infected came from an experi-
mental study, where the in vitro infection rate of
macrophages differentiated from peripheral blood
monocytes with L. panamensis was higher in
cutaneous leishmaniasis patients (from Tumaco)
than in asymptomatically infected persons (22).
Further evidence for genetic variation in
susceptibility comes from a comparison of leish-
maniasis symptoms in Amerindians and mixed
race people in Bolivia (23).
In the Opón focus, the geometric mean age for
clinical infections (3.8 years) was significantly
smaller than that for subclinical infections (8.7
years); but there was no significant gender
association with clinical symptoms. A positive
relationship between age and the proportion of
subclinical infections was also observed in Perú
where the geometric mean age for clinical infection
was significantly lower than those with subclinical
infections (7.7 and 15.0 years, respectively) and
in Tumaco too the odds that a skin test conver-
sion was associated with a lesion decreased sig-
nificantly with age: gender adjusted OR=0.2 for
adults (>30 year old) as compared with children
(<10 years old). This consistent pattern of a de-
creasing incidence of clinical infection with age
could be related to undetected acquired immunity
following infection (12). Alternatively, adults may
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be innately less susceptible to cutaneous leish-
maniasis (23) as they are to visceral leishmania-
sis (24), even in the absence of prior exposure to
leishmaniasis.
A novel hypothesis to explain the reduced
susceptibility to cutaneous leishmaniasis with age
comes from the recent findings that pre-exposure
to sandfly saliva reduces the clinical outcome of
L. major infection in experimental mice (25).
Antibodies to salivary gland antigens are thought
to cancel the enhancing immunomodulatory effects
from subsequent co-inoculation of saliva with the
Leishmania parasites (26). As adults living in
endemic areas have had a longer exposure to
sandfly bites than children, their presumed higher
levels of antibodies to sandfly antigen could
feasibly reduce their risk of clinical symptoms.
This speculative hypothesis is consistent with the
finding of a three-fold higher risk of clinical disease
for migrants compared to native inhabitants in Alto
Beni, Bolivia (23).
In Opón, people with previous clinical episodes
(i.e. scars) on average had 80% protection against
subsequent clinical infections, although this effect
was more marked amongst people who had a nega-
tive skin test response. Skin test responsiveness
was also a significant indicator of acquired pro-
tection, even amongst those with no clinical symp-
toms. Within the healthy population, the odds of a
subsequent clinical infection decreased by 22%
for each 1 mm increase in skin test size in Opón.
This corresponds with an equivalent measurement
of 18% in a Peruvian study of acquired immunity
following subclinical infections. Hence, the Opón
results confirm the conclusions from the Peruvian
study that protective immunity can be acquired
following a Leishmania infection even in the ab-
sence of clinical symptoms. This result provides
hope for the future development of vaccines. In
addition, it provides a rationale for using the
Montenegro skin test response as an indirect in-
dicator of the protection which may follow a puta-
tive vaccine within the context of an intervention
trial.
The recurrence rate of leishmaniasis in Opón (3%/
year) in the prospective study, was similar to
recurrence rates previously detected in Colombia
(L. panamensis), Perú (L. peruviana) and Brazil
(L. braziliensis): 2.0%/year (6), 2.9%/year (11),
and 2.7%/year (16) respectively. The consistency
of these data is remarkable given the differences
in the treatment regimes, parasite species, and
even in the definition of recurrence used by the
different research teams. On the Pacific coast of
Colombia, where L. panamensis was the most
common parasite isolated (27), the group of re-
current patients (80/498) required higher doses of
Glucantime® and showed a lower skin test re-
sponse compared with non-recurrent patients, sug-
gesting that the risk of reactivation is associated
with a low-cell mediated immune response.
In Opón, as in the Peruvian Andes, the incidence
rate of recurrence decreased dramatically during
the first 10 years following the primary lesion,
indicating that the majority of recurrent
leishmaniasis in this period is due mainly to
relapses rather than reinfections. On the
Colombian Pacific coast the cumulative frequency
of recurrences in a group of 498 patients also
increased rapidly in the first year after the first
lesion, with few recurrences detected during the
following 42 months of the follow up (12,27). From
this group of recurrent cases, 50% were suggested
to be caused by relapses based on the apparent
genetic identity of parasites isolated from the same
patient in both leishmaniasis episodes (primary
and secondary infections) (27). In all patients with
identical parasites in consecutive episodes, the
secondary lesions were located on the same part
of the body on the primary lesions. In the Opón
focus, 36% of recurrent lesions were located on
the same part of the body as the previous scars,
and this percentage decreased significantly with
time since primary lesion, indicating that the early
recurrences are more likely to be relapses and
the later recurrences are more likely to be
reinfections (presumably due to the loss of ac-
quired immunity).
Prior to the Opón study there were remarkably
few descriptions of the frequency and severity of
mucosal leishmaniasis following L. panamensis
infection. Most reports come from hospital/health
post admissions, which are notoriously biased, or
fail to take out account of the potential
confounding effect of time since the primary
cutaneous leishmaniasis episode. Nevertheless,
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the inclusion of suspected mucocutaneous
leishmaniasis patients based only on clinical
diagnosis may have selection bias and the results
have to be taken with precaution.  Active search
of rural populations are likely to encounter milder
mucocutaneous leishmaniasis symptoms than are
generally seen in mucocutaneous leishmaniasis
admissions, but may include more severe
mucocutaneous leishmaniasis symptoms than are
detected amongst cutaneous leishmaniasis
admissions (as the ratio of moderate: mild
mucocutaneous leishmaniasis symptoms
increases significantly with time since the
cutaneous leishmaniasis episode). With these
caveats, it seems that mucocutaneous
leishmaniasis due to L. panamensis in Colombia
lesions may be more severe than in Panamá: 23%
(25/108) of mucocutaneous leishmaniasis cases
in Opón and 17% (4/23) on the Colombian Pacific
Coast (28) had perforated nasal septa, compared
to 9% (3/33) in Panama (29). The cumulative
prevalence of mucocutaneous leishmaniasis
amongst cutaneous leishmaniasis patients was
also greater in Opón, 12%, than on the Colombian
Pacific Coast, 9% (10/114) (30).
Geographic variability in symptoms could be due
to genetic variability in parasite pathogenicity (31),
human susceptibility (32), or sand fly saliva
immunomodulatory activity (33). Alternative
explanations could involve variability in availability
of treatment. Prior to 1995 there were no medical
facilities available in Opón. While this could explain
the high frequency of chronic mucocutaneous
leishmaniasis lesions, we found no evidence that
treatment of cutaneous leishmaniasis lesions
reduced the risk of mucocutaneous leishmaniasis.
Our data indicated the reverse association,
presumably because the odds of treatment was
confounded by the severity of the cutaneous
leishmaniasis episode (a known correlate of
mucocutaneous leishmaniasis risk following L.
braziliensis infection) (30). Previous studies of
mucocutaneous leishmaniasis due to L.
braziliensis suggest that risk of mucocutaneous
leishmaniasis may decrease with age of primary
cutaneous leishmaniasis episode (31). Hence,
variability in the age distribution of cutaneous
leishmaniasis cases could also impact on the
frequency of mucocutaneous leishmaniasis
symptoms. In Opón cutaneous leishmaniasis
patients tend to be younger than on the Colombian
Pacific coast or in Panama, but we were unable
to detect any association between age and
mucocutaneous leishmaniasis risk.
The remaining three risk factors for
mucocutaneous leishmaniasis which we detected
in Opón were consistent with previous analyses
of mucocutaneous leishmaniasis risk associated
with L. braziliensis, but had not been previously
shown for L. panamensis. In particular, we found
that, as in Bahia, Brazil (34), people with cutaneous
leishmaniasis lesions on the head had significantly
greater risk of mucocutaneous leishmaniasis.
Secondly, we found that, as in Bolivia (35,36),
mucocutaneous leishmaniasis is a greater risk for
male than female cutaneous leishmaniasis
patients. While we cannot discount possible
confounders, it seems likely that this reflects
innate gender differences in susceptibility,
mediated by sex-associated hormones (37), as
demonstrated in laboratory mice infected with
various Leishmania species (38). Finally, we found
that, as in Belo Horizonte, Brazil (39),
mucocutaneous leishmaniasis patients had a
greater Montenegro skin test  response than
cutaneous leishmaniasis patients. This is
presumably because mucocutaneous leish-
maniasis, whether caused by L. braziliensis or L.
panamensis, is a hyperergic form of cutaneous
leishmaniasis with an exaggerated antigen-
specific, cell-mediated immune response (40).
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